Leuprolide Mesylate

DRUG2 trials

Sponsors

Foresee Pharmaceuticals Co., Ltd.

Conditions

Prostatic Neoplasms

Phase 3

Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma

CompletedNCT02234115

Foresee Pharmaceuticals Co., Ltd.Prostatic Neoplasms

Start: 2014-08-31End: 2017-01-05Updated: 2019-03-05

Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer

CompletedNCT03261999

Foresee Pharmaceuticals Co., Ltd.Prostatic Neoplasms

Start: 2017-09-26End: 2019-02-01Updated: 2020-05-04